Cancer Associated Thrombosis and Isoquercetin (CAT IQ)

Conditions:Lung Cancer, Lung Cancer, Colorectal Cancer, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology
Age Range:18 - Any
Start Date:January 2015
End Date:April 2023
Contact:Jeffrey Zwicker, MD

Use our guide to learn which trials are right for you!

Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.

This research study is evaluating a drug called isoquercetin to prevent venous thrombosis
(blood clots), in participants who have pancreas, non small cell lung cancer or colorectal

- This research study is a Phase II/III clinical trial.

--The goal of this trial is to evaluate if isoquercetin can prevent blood clots in
patients with pancreas, non small cell lung cancer or colorectal cancer. In the Phase II
part of this study, the investigators are looking for the dose of isoquercetin to reduce
D-dimer and demonstrate safety.

- Phase III Endpoint and Treatment Plan

- Primary Endpoint for Phase III portion of protocol: Cumulative incidence of VTE.

- Following the completion of the phase II portion, enrolled patients will be
randomized 1:1 to Arm C (isoquercetin) or Arm D (placebo). The dose for Arm C will
be determined after evaluation of the Phase II portion of the trial. The protocol
will be amended when the decision is made whether to proceed to Phase III and what
dose to use for Arm C. The study will be double-blinded to treatment arm. Lower
extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative
labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival
after completion of 56 days.

- At BIDMC, optional blood draw will be performed at time 0 and 4 hours following the
first dose of study drug.

Inclusion Criteria:

- Participants must meet the following criteria on screening examination to be eligible
to participate in phase 2 and 3 of the study:

- Participants must have histologically confirmed malignancy that is metastatic or
currently unresectable.

- Eligible malignancies include:

- Adenocarcinoma of the pancreas (currently unresectable or metastatic)

- Colorectal (stage IV)

- Non-small cell lung cancer (currently unresectable stage III or stage IV)

- Receiving or scheduled to receive first or second line chemotherapy (within 30 days of

- Minimum age 18 years. Because limited dosing or adverse event data are currently
available on the use of isoquercetin in participants <18 years of age, children are
excluded from this study but will be eligible for future pediatric isoquercetin

- Life expectancy of greater than 4 months.

- ECOG performance status ≤2 (see Appendix B ).

- Patient must be able to swallow capsules (phase III only)

- Participants must have preserved organ and marrow function as defined below:

- Absolute neutrophil count ≥1,000/mcL

- Platelets ≥ 90,000/mcL

- PT and PTT ≤ 1.5 x upper limit of normal

- Total bilirubin < 2.0 mg/dl

- AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal Creatinine <
2.0 mg/dl

- The effects of isoquercetin on the developing human fetus are unknown. For this
reason, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry and for the duration of study participation. Should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Participants may not be receiving any other study agents.

- Participants with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse events.

- Prior history of documented venous thromboembolic event within the last 2 years
(excluding central line associated events whereby patients completed anticoagulation).

- Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)

- History of significant hemorrhage (requiring hospitalization or transfusion) outside
of a surgical setting within the last 24 months

- Familial bleeding diathesis

- Known diagnosis of disseminated intravascular coagulation (DIC)

- Currently receiving anticoagulant therapy

- Current daily use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal),
aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of
higher doses of non-steroidal anti-inflammatory agents as determined by the treating
physician (e.g ibuprofen > 800 mg daily or equivalent).

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Known intolerance of niacin or ascorbic acid (including known G6PD deficiency)

- Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor
with the potential for teratogenic or abortifacient effects. Because there is an
unknown but potential risk of adverse events in nursing infants secondary to treatment
of the mother with isoquercetin, breastfeeding should be discontinued if the mother is
treated with isoquercetin. These potential risks may also apply to other agents used
in this study.
We found this trial at
Providence, Rhode Island 02908
Principal Investigator: Katherine Faricy-Anderson, MD
Phone: 401-732-7100
Providence, RI
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Principal Investigator: Jeffrey Zwicker, MD
Phone: 617-667-9299
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02130
Principal Investigator: Kenneth A. Bauer, MD
Phone: 857-364-5033
Boston, MA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Howard Liebman, MD
Phone: 323-865-0579
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Los Angeles, CA
Click here to add this to my saved trials
Sacramento, California 95655
Principal Investigator: Theodore Wun, MD
Phone: 916-734-1507
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Kristen Sanfilippo, MD
Phone: 314-362-0233
Saint Louis, MO
Click here to add this to my saved trials
Waltham, Massachusetts 02138
Principal Investigator: Thomas Caughey, MD
Phone: 617-497-9646
Waltham, MA
Click here to add this to my saved trials
50 Irving Street Northwest
Washington, District of Columbia 20422
Principal Investigator: Anita Aggarwal, DO, PhD
Phone: 202-745-8000
Click here to add this to my saved trials
950 Campbell Ave
West Haven, Connecticut 06516
(203) 932-5711
Principal Investigator: Ellice Wong, MD
Phone: 203-937-3421
VA Connecticut Healthcare System VA Connecticut encompasses an inpatient facility and Ambulatory Care Center in...
West Haven, CT
Click here to add this to my saved trials
White River Junction, Vermont 05009
Principal Investigator: Nancy Kuemmerle, DO, PhD
Phone: 802-295-9363
White River Junction, VT
Click here to add this to my saved trials
127 Long Sands Road
York, Maine 03909
Principal Investigator: Marilyn D. McLaughlin, MD
Phone: 207-351-3777
York, ME
Click here to add this to my saved trials